Pharmacokinetic and pharmacodynamic drug interactions in the treatment of XXXX .

@entity1 @entity5320 @entity11922 @entity101 @entity1774 @entity71 @entity1154 @entity1338 @entity4944 @entity16703 @entity2727
The psychostimulants @entity2727 , @entity4944 and @entity16703 are among the most common medications used today in @entity1 and adolescent psychiatry for the treatment of @entity1 with @entity71 . Frequently, these medications are used in combination with other medications on a short or long term basis. The present review examines psychostimulant pharmacology, summarises reported drug-drug interactions and explores underlying pharmacokinetic and pharmacodynamic considerations for interactions. A computerised search was undertaken using Medline (1966 to 2000) and Current Contents to provide the literature base for reports of drug-drug interactions involving psychostimulants. These leads were further cross-referenced for completeness of the survey. @entity2727 appears to be more often implicated in pharmacokinetic interactions suggestive of possible metabolic inhibition, although the mechanisms still remain unclear. @entity4944 was more often involved in apparent pharmacodynamic interactions and could potentially be influenced by medications affecting @entity5320 . No published reports of drug interactions involving @entity16703 were found. The alpha2-adrenergic agonists @entity1338 and @entity1774 have been implicated in several interactions. Perhaps best documented is their antagonism by tricyclic antidepressants and @entity11922 . In additional, concurrent beta-blocker use, or abrupt discontinuation, can lead to @entity101 response. Although there are few published well-controlled interaction studies with psychostimulants and alpha2-adrenergic agonists, it appears that these agents may be safely coadministered. The interactions of @entity1154 oxidase inhibitors with psychostimulants represent one of the few strict contraindications.
